Late Wilms tumor recurrence observed 32 years after diagnosis in a single case report
A Childhood Kidney Tumor Returned 32 Years Later
This systematic review analyzed a case report of a one-year-old female with bilateral, favorable-histology Wilms tumor.
Very late recurrence of childhood kidney cancer is extremely rare but possible, and this case reminds survivors and doctors that long-ago ca…
CFP10 immunohistochemistry shows high sensitivity for renal tuberculosis in surgical specimens
New Test Finds Hidden TB in Kidney Tissue
A retrospective cohort study of 86 patients with surgically resected renal tissue found CFP10 immunohistochemical staining had 91.8% sensiti…
A new kidney test spots hidden tuberculosis by finding a specific protein that standard methods often miss, helping doctors catch the infect…
Adjuvant intravesical BCG versus Epirubicin in intermediate-risk non-muscle invasive bladder cancer
A Common Bladder Cancer Treatment Extends Remission, But at a Cost
This randomized controlled trial compared adjuvant intravesical BCG and Epirubicin in 122 patients with intermediate-risk non-muscle invasiv…
For a common bladder cancer, one treatment keeps the disease away longer, but the other may offer a better daily life.
Meta-analysis shows ERAS care improves recovery and reduces complications in laparoscopic nephrectomy for renal cancer
ERAS Care Helps Kidney Cancer Patients Heal Faster
This meta-analysis evaluated enhanced recovery after surgery (ERAS) versus traditional care in 2,361 patients undergoing laparoscopic radica…
Kidney cancer patients recovering from surgery heal faster with a special plan, eating and walking sooner while spending less time in the ho…
Phase II trial finds adding gemcitabine to cisplatin-radiotherapy does not improve 2-year disease-free survival in muscle-invasive bladder cancer
Adding gemcitabine to cisplatin did not improve disease-free survival in bladder cancer patients
A Phase II randomized trial in 69 patients with pT2-pT3N0M0 muscle-invasive bladder cancer found similar 2-year disease-free survival (58.3%…
Adding gemcitabine to cisplatin radiotherapy did not improve disease-free survival for bladder cancer patients, with similar two-year rates …
Audit plus peer comparison improved documentation of tumour features and resection completeness in non-muscle-invasive bladder cancer surgery
Audit and feedback improved documentation of bladder cancer surgery details in a large trial
This cluster randomised controlled trial involved 14,915 patients undergoing transurethral resection of bladder tumour surgery across 201 si…
This large study examined whether adding peer comparison and education to standard audits changed how bladder cancer surgery was performed.
Neoadjuvant sacituzumab govitecan plus pembrolizumab shows 39% clinical complete response in MIBC
Drug combination shows promise for bladder cancer patients who cannot take standard chemotherapy
A single-arm phase 2 study of 49 patients with muscle-invasive bladder cancer ineligible for cisplatin found a clinical complete response ra…
A new drug combination helped 39% of bladder cancer patients who couldn't take standard chemotherapy achieve a complete response before surg…
Spinal anesthesia associated with lower recurrence than general anesthesia in non-muscle invasive bladder cancer
Spinal anesthesia linked to lower bladder cancer recurrence rates in single hospital study
A single-center randomized trial of 287 patients with non-muscle invasive bladder cancer found spinal anesthesia was associated with lower 2…
Patients with early-stage bladder cancer had lower recurrence rates when spinal anesthesia was used instead of general anesthesia during tum…
CD8 PET imaging shows modest correlation with biopsy CD8 counts in solid tumor patients on immunotherapy
New imaging method shows modest link to immune cell counts in solid tumors
A Phase II prospective multicenter study of 49 patients with solid tumors receiving immune checkpoint blockade found a modest correlation (c…
A new PET scan shows a modest link to immune cell counts inside solid tumors, with stronger results in kidney cancer patients.
PI3K-AKT-mTOR pathway activation linked to renal cell carcinoma progression in review
Review explores potential kidney cancer treatment target and challenges
A review article summarizes literature on the PI3K-AKT-mTOR signaling pathway in renal cell carcinoma (RCC).
Kidney cancer tumors often overactivate a cell pathway that drives growth and spreading, prompting doctors to explore blocking it with new d…